Abstract P3-05-08: Lymphoid and myeloid cell characterization of inflammatory breast cancer tumor microenvironment and correlation to pathological complete response

Myeloid Cell ◽

Complete Response ◽

Cell Characterization ◽

Cancer Tumor

Abstract P3-16-01: Immune characterization of inflammatory breast cancer and correlation to pathological complete response

10.1158/1538-7445.sabcs16-p3-16-01 ◽

2017 ◽

Author(s):

SM Reddy ◽

JA Wargo ◽

A Reuben ◽

J Reuben ◽

W Woodward ◽

...

Keyword(s):

Breast Cancer ◽

Complete Response

P1-14-02: Correlation of Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) with Pathological Complete Response (pCR) during Neoadjuvant Chemotherapy (CT) Combined with Bevacizumab in HER2 Negative Inflammatory Breast Cancer (IBC): Ancillary Study of Phase II Trial BEVERLY 1.

10.1158/0008-5472.sabcs11-p1-14-02 ◽

2011 ◽

Author(s):

J-Y Pierga ◽

F-C Bidard ◽

F Andre ◽

T Petit ◽

F Dalenc ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Tumor Cells ◽

Phase Ii Trial ◽

Complete Response ◽

Circulating Endothelial Cells ◽

Ancillary Study

Abstract P6-12-03: Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy

10.1158/0008-5472.sabcs13-p6-12-03 ◽

2013 ◽

Author(s):

H Masuda ◽

M Chavez-Mac Gregor ◽

DD Liu ◽

RH Alvarez ◽

S Krishnamurthy ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Outcome ◽

Systemic Chemotherapy ◽

Complete Response ◽

Poor Clinical Outcome

Abstract OT1-02-05: A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy

10.1158/1538-7445.sabcs17-ot1-02-05 ◽

2018 ◽

Author(s):

A Alexander ◽

J Willey ◽

H Sun ◽

CA Parker ◽

AN Marx ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormonal Therapy ◽

Hormone Receptor ◽

Phase Ii Study ◽

Complete Response

Pathological complete response (pCR) is not a good marker for inflammatory breast cancer (IBC) patients to predict improved long-term survival after neoadjuvant chemotherapy (NT)

Annals of Oncology ◽

10.1093/annonc/mdv117.13 ◽

2015 ◽

Vol 26 ◽

pp. iii15

Author(s):

F. Fei ◽

L. Tang ◽

G. Di

Keyword(s):

Breast Cancer ◽

Complete Response ◽

Term Survival ◽

Long Term Survival ◽

Good Marker

Abstract 3145: Characterization of novel immune checkpoint receptors within the breast cancer tumor microenvironment

10.1158/1538-7445.am2018-3145 ◽

2018 ◽

Author(s):

Austin D. Williams ◽

Jean S. Campbell ◽

Lauri D. Aicher ◽

Kyle K. Payne ◽

Jose R. Conejo-Garcia ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Microenvironment ◽

Immune Checkpoint ◽

Cancer Tumor ◽

Checkpoint Receptors

Characterization of Novel Immune Checkpoint Receptors within the Breast Cancer Tumor Microenvironment

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2017.07.024 ◽

2017 ◽

Vol 225 (4) ◽

pp. S21

Author(s):

Austin D. Williams ◽

Kyle K. Payne ◽

Alycia So ◽

Jose Conejo-Garcia ◽

Julia C. Tchou

Keyword(s):

Breast Cancer ◽

Tumor Microenvironment ◽

Immune Checkpoint ◽

Cancer Tumor ◽

Checkpoint Receptors

Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.108 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 108-108 ◽

Cited By ~ 1

Author(s):

Jean-Yves Pierga ◽

Francois-Clement Bidard ◽

Aurelie Autret ◽

Thierry Petit ◽

Fabrice Andre ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Tumor Cells ◽

Complete Response ◽

Pooled Analysis ◽

Phase Ii Trials ◽

Multicentre Phase

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Annals of Oncology ◽

10.1093/annonc/mdw535 ◽

2017 ◽

Vol 28 (1) ◽

pp. 103-109 ◽

Cited By ~ 25

Author(s):

J.-Y. Pierga ◽

F.-C. Bidard ◽

A. Autret ◽

T. Petit ◽

F. Andre ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Complete Response ◽

Pooled Analysis ◽

Circulating Tumour Cells ◽

Phase Ii Trials ◽

Multicentre Phase

Faculty Opinions recommendation of Molecular characterization of the tumor microenvironment in breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1020390.232561 ◽

2004 ◽

Author(s):

Dinah Singer

Keyword(s):

Breast Cancer ◽

Tumor Microenvironment ◽

Molecular Characterization